These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 33159215)

  • 1. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
    Macchini M; Peretti U; Orsi G; Zanon S; Mazza E; Valente MM; Tamburrino D; Belfiori G; Rossi G; Testoni SGG; Passoni P; Doglioni C; Cascinu S; Reni M
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):95-101. PubMed ID: 33159215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
    Hitchen N; Waldron NR; Deva S; Findlay M; Lawrence B
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e231-e238. PubMed ID: 36114593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
    Orsi G; Di Marco M; Cavaliere A; Niger M; Bozzarelli S; Giordano G; Noventa S; Rapposelli IG; Garajova I; Tortora G; Rodriquenz MG; Bittoni A; Penzo E; De Lorenzo S; Peretti U; Paratore C; Bernardini I; Mosconi S; Spallanzani A; Macchini M; Tamburini E; Bencardino K; Giommoni E; Scartozzi M; Forti L; Valente MM; Militello AM; Cascinu S; Milella M; Reni M
    ESMO Open; 2021 Oct; 6(5):100238. PubMed ID: 34392104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients.
    Yang SH; Guo JC; Hsu C; Kuo SH; Tien YW; Cheng AL; Yeh KH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):97-105. PubMed ID: 30852003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
    Wagener DJ; Hoogenraad WJ; Rougier P; Lusinchi A; Taal BG; Veenhof CH; de Graeff A; Conroy T; Curran D; Sahmoud T; Wils J
    Eur J Cancer; 1996 Jul; 32A(8):1310-3. PubMed ID: 8869091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Katopodis O; Polyzos A; Kentepozidis N; Giassas S; Rovithi M; Bozionelou V; Kalbakis K; Vamvakas L; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):361-8. PubMed ID: 20428874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.
    Macchini M; Chiaravalli M; Pircher C; Zanon S; Peretti U; Mazza E; Valente MM; Fugazza C; Gianni L; Reni M
    Dig Liver Dis; 2021 Jan; 53(1):117-121. PubMed ID: 32631650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
    Crippa S; Bittoni A; Sebastiani E; Partelli S; Zanon S; Lanese A; Andrikou K; Muffatti F; Balzano G; Reni M; Cascinu S; Falconi M
    Eur J Surg Oncol; 2016 Oct; 42(10):1533-9. PubMed ID: 27423449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
    Strauss VY; Shaw R; Virdee PS; Hurt CN; Ward E; Tranter B; Patel N; Bridgewater J; Parsons P; Radhakrishna G; O'Neill E; Sebag-Montefiore D; Hawkins M; Corrie PG; Maughan T; Mukherjee S
    BMC Cancer; 2019 Feb; 19(1):121. PubMed ID: 30717707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
    Milella M; Gelibter A; Di Cosimo S; Bria E; Ruggeri EM; Carlini P; Malaguti P; Pellicciotta M; Terzoli E; Cognetti F
    Cancer; 2004 Jul; 101(1):133-8. PubMed ID: 15221998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology.
    Hao C; Ma X; Wang L; Zhang W; Hu J; Huang J; Yang W
    Eur J Clin Pharmacol; 2021 Apr; 77(4):595-605. PubMed ID: 33179758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
    Murray Stewart T; Von Hoff D; Fitzgerald M; Marton LJ; Becerra CHR; Boyd TE; Conkling PR; Garbo LE; Jotte RM; Richards DA; Smith DA; Stephenson JJ; Vogelzang NJ; Wu HH; Casero RA
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):135-144. PubMed ID: 33215270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
    Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report.
    Martin Huertas R; Fuentes-Mateos R; Serrano Domingo JJ; Corral de la Fuente E; Rodríguez-Garrote M
    World J Clin Oncol; 2020 Oct; 11(10):844-853. PubMed ID: 33200077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
    Ruddy KJ; Schaid DJ; Batzler A; Cecchini RS; Partridge AH; Norman A; Fehrenbacher L; Stewart EA; Trabuco E; Ginsburg E; Couch FJ; Fasching PA; Vachon C; Ganz PA
    J Natl Cancer Inst; 2021 Aug; 113(8):1105-1108. PubMed ID: 33159444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
    Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
    Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.